Research programme: muscular dystrophy gene therapy - Tapestry Pharmaceuticals

Drug Profile

Research programme: muscular dystrophy gene therapy - Tapestry Pharmaceuticals

Alternative Names: DMD gene therapy - NaPro BioTherapeutics; Muscular dystrophy gene therapy - NaPro BioTherapeutics

Latest Information Update: 10 Aug 2005

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tapestry Pharmaceuticals
  • Class Gene therapies
  • Mechanism of Action Genetic transcription inhibitors; Genetic transcription stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Muscular dystrophies

Most Recent Events

  • 10 Aug 2005 Discontinued - Preclinical for Muscular dystrophy in USA (unspecified route)
  • 11 May 2004 Napro Biotherapeutics is now called Tapestry Pharmaceuticals
  • 11 Dec 2003 Preclinical trials in Muscular dystrophy in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top